NCT03922204View on ClinicalTrials.gov

A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 8, 2019

Primary Completion Date

November 7, 2024

Study Completion Date

November 7, 2024

Conditions
Advanced CancerSolid Tumor, AdultB-cell Lymphoma, Adult
Interventions
DRUG

MCLA-145

full-length IgG1 bispecific antibody specifically targeting PD-L1 and CD137

DRUG

Pembrolizumab (Keytruda)

Group B patients will be treated in combination with MCLA-145 and pembrolizumab 200mg Q3W.

Trial Locations (8)

2650

University Hospital Antwerp, Antwerp

9000

Universitair Ziekenhuis Gent, Ghent

10065

Memorial Sloan Kettering Cancer Center, New York

92093-0987

Moores Cancer Centre, La Jolla

02215

Dana-Farber Cancer Institute, Boston

1066CX

Netherlands Cancer Institute, Amsterdam

28040 EP

Hospital Universitario Fundarcion Jimenez Diaz, Madrid

31008 EP

Clinica Universidad de Navarra, Pamplona

All Listed Sponsors
lead

Merus N.V.

INDUSTRY

NCT03922204 - A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies | Biotech Hunter | Biotech Hunter